Last reviewed · How we verify
Topical Dexamethasone
At a glance
| Generic name | Topical Dexamethasone |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (PHASE3)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Dextenza in the Post-op Management of Vitreoretinal Surgeries (PHASE4)
- Study of TN-001 Topical Eyedrops for Keratoconus (PHASE1, PHASE2)
- Parasitic Ulcer Treatment Trial (PHASE3)
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) (PHASE2, PHASE3)
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |